Bench-to-bedside review: the role of nitric oxide in sepsis.

Abstract:

:Sepsis is a state of systemic inflammation directed at microbes or their toxins in blood or tissues. Nitric oxide (NO) is one of many vasoactive molecules released from a variety of cell types during sepsis. Almost two decades ago, NO emerged as a potential therapeutic target in sepsis. NO produced by the constitutive NO synthase (NOS) isoform (endothelial NOS and neuronal NOS) in the vascular endothelium and elsewhere acts as a nonadrenergic, noncholinergic neurotransmitter, an inhibitor of platelet aggregation and a vasodilator. During sepsis, activation of inducible NOS (iNOS) in the lung epithelium and other organs occurs, leading to NO overproduction. The result of excessive circulating NO is enhanced bacterial destruction, but also profound vasodilatation, activation of inflammatory cascades and depression of cardiac function. Trials of nonselective NOS inhibitors have shown increased mean arterial pressure, but also increased pulmonary artery pressure and reduced cardiac output. Small animal studies of iNOS selective inhibition have produced dichotomous results, but larger clinical studies assessing mortality are lacking. Inhaled NO has been touted as a therapeutic option to improve systemic oxygenation in the acute lung injury of sepsis (hypoxic pulmonary vasoconstriction and pulmonary hypertension); however, studies of inhaled NO in acute respiratory distress syndrome have not shown survival efficacy. Further investigation into the role of NO in human sepsis, and the development of methods to assess NO balance in patients with sepsis is essential in this field. In this review, we outline the effects of NO in sepsis, and summarize the therapeutic outcomes of NOS inhibitors, and inhaled NO in sepsis and acute respiratory distress syndrome.

journal_name

Expert Rev Respir Med

authors

De Cruz SJ,Kenyon NJ,Sandrock CE

doi

10.1586/ers.09.39

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

511-21

issue

5

eissn

1747-6348

issn

1747-6356

journal_volume

3

pub_type

杂志文章
  • Role of caveolin-1 in asthma and chronic inflammatory respiratory diseases.

    abstract::Caveolin-1 (Cav-1) is the major protein present in invaginations of the plasma membrane of cells known as caveolae. Cav-1 is expressed in numerous resident and inflammatory cells implicated in the pathogenesis of asthma and chronic inflammatory respiratory diseases including chronic obstructive pulmonary disease. A re...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2014.905915

    authors: Royce SG,Le Saux CJ

    更新日期:2014-06-01 00:00:00

  • Emerging biomarkers of lymphangioleiomyomatosis.

    abstract:INTRODUCTION:Lymphangioleiomyomatosis (LAM) is a destructive lung disease affecting primarily women. LAM is caused by inactivating mutations in the tuberous sclerosis complex (TSC) genes, resulting in hyperactivation of mechanistic/mammalian target of rapamycin complex 1 (mTORC1). Over the past five years, there have b...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1409622

    authors: Nijmeh J,El-Chemaly S,Henske EP

    更新日期:2018-02-01 00:00:00

  • Genetics and genomics in human lung transplantation.

    abstract::Lung transplantation is the only effective treatment for many advanced lung diseases. However, long-term survival after transplantation remains relatively poor, thus limiting the application of lung transplantation to patients with end-stage disease only. Acute and chronic rejection is the main reason for allograft fa...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.1.2.271

    authors: Garantziotis S,Palmer SM

    更新日期:2007-10-01 00:00:00

  • Which is the optimal bronchodilator therapy for chronic obstructive pulmonary disease?

    abstract::Chronic obstructive pulmonary disease is an inflammatory disorder characterized by airflow limitation. Its cardinal symptom is dyspnea, which develops gradually with even low levels of exercise. Bronchodilators (BDs) are the most effective drugs for relieving dyspnea. Two main types of BD are currently available, β-mi...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.13.18

    authors: Baloira A

    更新日期:2013-04-01 00:00:00

  • Aerosolized antibiotics in cystic fibrosis: an update.

    abstract::Inhaled antibiotic therapy, targeting Pseudomonas aeruginosa, is a fundamental component of cystic fibrosis (CF) management. Tobramycin inhalation solution (TIS) was approved in the United States (US) in 1998. Subsequent research efforts focused on developing products with a reduced treatment time burden. Aztreonam fo...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2014.896205

    authors: Fiel SB

    更新日期:2014-06-01 00:00:00

  • Assessment and monitoring of cystic fibrosis lung disease in infants and young children.

    abstract::Chronic airway infection and inflammation are the hallmarks of cystic fibrosis (CF) lung disease. As these events occur early in life, it is critical to develop techniques for the assessment and monitoring of early-CF lung disease in infants and young children. In the last several years, there have been major advances...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.2.3.381

    authors: Ren CL

    更新日期:2008-06-01 00:00:00

  • Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.

    abstract::Reslizumab, a neutralizing anti-IL-5 monoclonal antibody, is a promising adjunctive treatment for severe eosinophilic asthma. Monthly intravenous 3.0 mg/kg reslizumab had resulted in improvements in lung function and asthma control. It is well tolerated and common adverse events include headache, nasopharyngitis and u...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2015.1000867

    authors: Lim HF,Nair P

    更新日期:2015-04-01 00:00:00

  • Biomarkers of latent TB infection.

    abstract::For the last 100 years, the tuberculin skin test (TST) has been the only diagnostic tool available for latent TB infection (LTBI) and no biomarker per se is available to diagnose the presence of LTBI. With the introduction of M. tuberculosis-specific IFN-gamma release assays (IGRAs), a new area of in vitro immunodiagn...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/ers.09.31

    authors: Ruhwald M,Ravn P

    更新日期:2009-08-01 00:00:00

  • The physical basis of ventilator-induced lung injury.

    abstract::Although mechanical ventilation (MV) is a life-saving intervention for patients with acute respiratory distress syndrome (ARDS), it can aggravate or cause lung injury, known as ventilator-induced lung injury (VILI). The biophysical characteristics of heterogeneously injured ARDS lungs increase the parenchymal stress a...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.10.28

    authors: Plataki M,Hubmayr RD

    更新日期:2010-06-01 00:00:00

  • Recent advances in optical coherence tomography for the diagnoses of lung disorders.

    abstract::There have been many advances in the field of diagnostic and therapeutic pulmonary medicine in the past several years, with major progress in the field of imaging. Optical coherence tomography (OCT) is a high-resolution (micron level) imaging modality currently being advanced with the potential to image airway wall st...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.11.59

    authors: Hou R,Le T,Murgu SD,Chen Z,Brenner M

    更新日期:2011-10-01 00:00:00

  • Growing old with asthma: what are the changes and challenges?

    abstract::Asthma is a disease that affects approximately 7% of adults residing in the USA; the prevalence is even greater in children and approaches 10%. The CDC has reported that the overall prevalence of lifetime asthma is 10.5%. New-onset asthma is most often seen in children and is associated with atopy; however, the majori...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.10.12

    authors: Braman SS

    更新日期:2010-04-01 00:00:00

  • Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.

    abstract::Premature infants are at substantial risk for a spectrum of morbidities that are gestational age dependent. Respiratory syncytial virus (RSV) infection is most common in the first two years of life with the highest burden in children aged <6 months. Preterm infants ≤35 weeks' gestation are handicapped by incomplete im...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2015.1098536

    authors: Abraha HY,Lanctôt KL,Paes B

    更新日期:2015-01-01 00:00:00

  • Physical functional capacity in idiopathic pulmonary fibrosis: performance characteristics of the continuous-scale physical function performance test.

    abstract:BACKGROUND:Physical functional capacity is impaired in idiopathic pulmonary fibrosis (IPF). There is no tool to measure this key clinical outcome. The continuous-scale physical function performance (CS-PFP) test is one that assesses activities of daily living, but it has never been used in IPF. METHODS:We determined i...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.2015.1030396

    authors: Olson AL,Swigris JJ,Belkin A,Hannen L,Yagihashi K,Schenkman M,Brown KK

    更新日期:2015-06-01 00:00:00

  • Mometasone furoate/formoterol in the treatment of persistent asthma.

    abstract::Mometasone furoate and formoterol fumarate dihydrate (MF/F) administered via metered-dose inhaler with a dose counter is a new fixed-dose combination of an inhaled corticosteroid and a long-acting β2-agonist indicated for daily maintenance therapy in patients aged ≥12 years with persistent asthma. Randomized, controll...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.11.71

    authors: Berger WE

    更新日期:2011-12-01 00:00:00

  • Exploring the clinical relevance of cough hypersensitivity syndrome.

    abstract::Introduction: Knowledge of the pathophysiology of cough has continued to advance over recent decades. Establishing anatomic-diagnostic protocols, based on the anatomy and distribution of vagus nerve pathways regulating the cough reflex, was the first breakthrough in modern clinical medicine for chronic cough. The unme...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1080/17476348.2020.1713102

    authors: Song WJ,Chung KF

    更新日期:2020-03-01 00:00:00

  • Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers.

    abstract:INTRODUCTION:Malignant pleural effusion (MPE) is a feature of metastatic cancer associated with significant morbidity and cost. The typical management of MPE is systemic chemotherapy and mechanical intervention. Vascular endothelial growth factor (VEGF), an inducer of vascular permeability, has been shown to mediate fl...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1417042

    authors: Sabang RL,Gandhiraj D,Fanucchi M,Epelbaum O

    更新日期:2018-02-01 00:00:00

  • Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.

    abstract::Background: Few studies have provided real-world evidence of mepolizumab efficacy and safety. We aimed to evaluate mepolizumab for severe eosinophilic asthma in daily clinical practice.Research design and methods: Patients included in the RINOVA (Interdisciplinary Network for the management of severe asthma in Veneto ...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1080/17476348.2019.1676734

    authors: Caminati M,Cegolon L,Vianello A,Chieco Bianchi F,Festi G,Marchi MR,Micheletto C,Mazza F,Tognella S,Senna G

    更新日期:2019-12-01 00:00:00

  • Pharmacological treatment of refractory breathlessness.

    abstract::Refractory breathlessness is one of the most common and devastating symptoms of advanced cardiorespiratory disease, both malignant and nonmalignant. In spite of increased interest in research in the last 20 years, there have been few significant advances in the palliation of this distressing condition. The most succes...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.3.1.21

    authors: Booth S,Bausewein C,Higginson I,Moosavi SH

    更新日期:2009-02-01 00:00:00

  • Treatment in resectable, locally advanced NSCLC: which is the best approach?

    abstract::Non-small-cell lung cancer is the most common cause of cancer-related death worldwide. Surgery remains the cornerstone of treatment for localized, resectable lung cancer, although advanced stages are associated with a high risk of developing distant metastases. Large randomized trials have demonstrated an improvement ...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.2.5.655

    authors: Kueng MM,Betticher DC

    更新日期:2008-10-01 00:00:00

  • Emerging pharmacotherapies in cystic fibrosis.

    abstract:INTRODUCTION:Cystic fibrosis (CF) is an autosomal dominant chloride channelopathy caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that results clinically in a multisystem disorder. The major source of morbidity and mortality in CF is lung disease, which is characterized by recurrent cycles...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1512409

    authors: McElvaney OJ,Gunaratnam C,McElvaney OF,Bagwe I,Reeves EP,McElvaney NG

    更新日期:2018-10-01 00:00:00

  • Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.

    abstract::The Understanding Potential Long-term Improvements in Function with Tiotropium (UPLIFT) trial was a global 4-year randomized placebo-controlled clinical trial that evaluated the long-term impact of tiotropium bromide 18 microg once daily on the accelerated age-related decline in pre- and post-bronchodilator forced exp...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.10.23

    authors: Tashkin DP

    更新日期:2010-06-01 00:00:00

  • An overview of the available treatments for chronic cavitary pulmonary aspergillosis.

    abstract:INTRODUCTION:Chronic pulmonary aspergillosis (CPA) is a chronic lung infection caused by Aspergillus fumigatus, that complicates structural lung diseases. Of the different types of CPA, chronic cavitary pulmonary aspergillosis (CCPA) is the most common form. The mainstay of treatment of CCPA is oral triazoles. However,...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1080/17476348.2020.1750956

    authors: Sehgal IS,Dhooria S,Muthu V,Prasad KT,Agarwal R

    更新日期:2020-07-01 00:00:00

  • Should vitamin K be supplemented instead of antagonised in patients with idiopathic pulmonary fibrosis?

    abstract:INTRODUCTION:There is an ongoing need for additional interventions in idiopathic pulmonary fibrosis (IPF) as antifibrotic drugs currently available only inhibit and do not stall disease progression. Vitamin K is a co-factor for the activation of coagulation factors. However, it is also required to activate proteins wit...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1080/17476348.2018.1424544

    authors: De Brouwer B,Piscaer I,Von Der Thusen JH,Grutters JC,Schutgens RE,Wouters EF,Janssen R

    更新日期:2018-03-01 00:00:00

  • The long-lasting effects of the acute respiratory distress syndrome.

    abstract::Introduction: Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury common in critically ill patients and characterized by significant morbidity and mortality. It frequently manifests long-lasting effects beyond hospitalization, from cognitive impairment to physical weakness.Areas covered: S...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1080/17476348.2020.1743182

    authors: Mart MF,Ware LB

    更新日期:2020-06-01 00:00:00

  • Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.

    abstract:INTRODUCTION:N-acetyl-l-cysteine (NAC), a derivative of the naturally occurring amino acid l-cysteine, is a mucolytic agent that may also act as an antioxidant by providing cysteine intracellularly for increased production of glutathione. It is also used for the treatment of acetaminophen overdose. Areas covered: The r...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1495562

    authors: Calzetta L,Matera MG,Rogliani P,Cazzola M

    更新日期:2018-08-01 00:00:00

  • Smoking and nonsmoking asthma: differences in clinical outcome and pathogenesis.

    abstract::Cigarette smoking in asthma is frequently present and is associated with worsening of symptoms, accelerated lung-function decline, a higher frequency of hospital admissions, a higher degree of asthma severity, poorer asthma control and reduced responsiveness to corticosteroids. Furthermore, it is associated with reduc...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.10.85

    authors: Fattahi F,Hylkema MN,Melgert BN,Timens W,Postma DS,ten Hacken NH

    更新日期:2011-02-01 00:00:00

  • Respiratory muscle involvement in sarcoidosis.

    abstract:INTRODUCTION:In sarcoidosis, muscle involvement is common, but mostly asymptomatic. Currently, little is known about respiratory muscle and diaphragm involvement and function in patients with sarcoidosis. Reduced inspiratory muscle strength and/or a reduced diaphragm function may contribute to exertional dyspnea, fatig...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1480940

    authors: Schreiber T,Windisch W

    更新日期:2018-07-01 00:00:00

  • Ultrasound in the management of pleural disease.

    abstract:INTRODUCTION:Pleural disease encompasses a large range of conditions, is a common presentation to the acute medical take and often requires comprehensive investigation and treatment. Ultrasound is well recognised as a useful investigative tool in pleural disease especially in the field of pleural effusion, pleural thic...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2017.1300531

    authors: Mercer RM,Psallidas I,Rahman NM

    更新日期:2017-04-01 00:00:00

  • Allergic airway inflammation: unravelling the relationship between IL-37, IL-18Rα and Tir8/SIGIRR.

    abstract::The hallmarks of allergic bronchial asthma arise from chronic airway inflammation. Thus, elucidating the mechanisms regulating the maintenance of this chronic inflammatory response is key to understanding asthma pathogenesis. To date, it is not clear whether a predominance of proinflammatory factors or a reduced capac...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2015.1109452

    authors: Lunding L,Schröder A,Wegmann M

    更新日期:2015-01-01 00:00:00

  • Management of pleural infections.

    abstract:INTRODUCTION:The management of infected pleural effusion is complex. Therapeutic resolution requires determining the following: appropriate antibiotic regimen, the need for pleural drainage, the optimal drainage tube size, and the need for intrapleural therapy or surgery. Areas covered: An updating of the latest advanc...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1475234

    authors: Ferreiro L,Porcel JM,Bielsa S,Toubes ME,Álvarez-Dobaño JM,Valdés L

    更新日期:2018-06-01 00:00:00